Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
- Details
- Category: Novo Nordisk
Novo Nordisk has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924.
FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States (US) Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Genzyme Reports Fourth-Quarter Revenue
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported that preliminary fourth-quarter revenue was $1.08 billion, compared with $1.17 billion in the same period in 2008. For the year, revenue was $4.5 billion compared with $4.6 billion in 2008. Excluding the Genetic Disease business, which was affected by a product supply interruption, fourth-quarter revenue grew 24 percent compared with the same period in 2008 and full-year revenue grew 15 percent.
Novartis launches schizophrenia treatment Fanapt in the US
- Details
- Category: Novartis
Novartis announced that Fanapt(TM) (iloperidone) tablets are now available for use across the US for the acute treatment of schizophrenia in adults. Fanapt is a twice-daily, oral antipsychotic, approved by the US Food and Drug Administration (FDA) in May 2009.
Abbott's XIENCE V(R) Approved in Japan - Second Largest Drug Eluting Stent Market Worldwide
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. Japan is the second largest drug eluting stent market in the world after the United States, with approximately 200,000 stent procedures performed each year.
AstraZeneca Reaches Agreements With Teva Pharmaceuticals
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement with Teva Pharmaceutical Industries Ltd. and affiliates (collectively "Teva") to settle patent litigation regarding Teva's proposed generic version of AstraZeneca's Nexium delayed-release capsules (esomeprazole magnesium).
Pfizer and Strides Arcolab to Collaborate on Generic Products
- Details
- Category: Pfizer
Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ownership interest.
More Pharma News ...
- Luitpold Pharmaceuticals, Inc. Acquires PharmaForce, Inc.
- All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization
- Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine
- Sanofi-aventis to Acquire Chattem Inc. Creating a Strong U.S. Consumer Healthcare Platform
- FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
- Sanofi Pasteur to Develop & Commercialize Vaccine to Prevent Staphylococcus infections
- GSK publishes speaking, consulting fees paid to US healthcare professionals